KIRON M DAS
Medical Practice in Basking Ridge, NJ
License number
New Jersey 25MA03579700
Issued Date
Feb 16, 1979
Expiration Date
Jun 30, 2017
Category
Medical Examiners
Type
Medical Doctor
Address
Address
Basking Ridge, NJ
Professional information
Chemoprevention Of Colorectal Cancer By Mesalamine/Sulfasalazine
US Patent:
2011005, Mar 10, 2011
Filed:
May 17, 2006
Appl. No.:
11/914849
Inventors:
Kiron M. Das - Basking Ridge NJ, US
Jim Chung-Chin Lin - Iowa City IA, US
Jim Chung-Chin Lin - Iowa City IA, US
Assignee:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - New Brunswick NJ
International Classification:
A61K 31/655, A61K 31/196, C09B 29/00, C07C 229/64, A61P 35/00, C12Q 1/68, G01N 33/566
US Classification:
514150, 514567, 534664, 562444, 435 6, 435 721
Abstract:
A method for preventing or treating colorectal cancer in a patient possessing human tropomyocin isoform TC22 is presented. Also presented is a method for evaluating TC22 expression reduction activity of a compound.
In-Vitro Model Of The Transformation Of Metaplasia To Neoplasia
US Patent:
2010030, Dec 2, 2010
Filed:
Mar 25, 2010
Appl. No.:
12/731995
Inventors:
Kiron Das - Basking Ridge NJ, US
International Classification:
C12Q 1/02
US Classification:
435 29
Abstract:
This invention relates to a novel in-vitro model of transformation of a benign Barrett's cell line to a neoplastic cell line following repeated exposure to acid and bile over the course of about 65 wks, and to the process of using the model to study the transformation.
Tropomyosin Isoforms, And Diagnostic And Therapeutic Uses Therefor
US Patent:
7285630, Oct 23, 2007
Filed:
Jul 22, 2002
Appl. No.:
10/201501
Inventors:
Kiron M. Das - Basking Ridge NJ, US
Jim Jung-Chin Lin - Iowa City IA, US
Jim Jung-Chin Lin - Iowa City IA, US
Assignee:
University of Medicine and Dentistry of New Jersey - New Brunswick NJ
University of Iowa Research Foundation - Iowa City IA
University of Iowa Research Foundation - Iowa City IA
International Classification:
C07K 14/00
US Classification:
530350, 530326, 4241851, 435 71
Abstract:
A novel isoform of tropomyosin is disclosed. The isoform is closely related to epithelial human tropomyosin (hTM) and more particularly to hTM5 except the last coding exon. The novel isoform, is called TC22. Northern blot analysis with TC22-specific probe revealed that normal culture cell lines and normal epithelial tissues expressed very little, if at all, TC22 message, whereas their transformed counterparts and tumor tissues including dysfunction of the alimentary canal, significantly increased the expression of TC22. Assays directed at determining the level of TC22 are useful in diagnostics and therapeutics of dysfunction of the alimentary canal. Specific antibodies and mimics for TC22 are also disclosed for use in diagnostics and therapeutics of dysfunction of the alimentary canal.
Treatment Of Ulcerative Colitis With Tropomyosin Isoforms And Monoclonal Antibodies To Tropomyosin Isoforms
US Patent:
7264807, Sep 4, 2007
Filed:
May 1, 2003
Appl. No.:
10/427196
Inventors:
Kiron M. Das - Basking Ridge NJ, US
Assignee:
University of Medicine and Dentistry of New Jersey - New Brunswick NJ
International Classification:
A61K 39/395
US Classification:
4241521, 4241391, 4241561, 5303881, 5303879
Abstract:
This invention pertains to a method for treating ulcerative colitis. Specifically, the method comprises orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of an antibody which binds to a tropomyosin isoform associated with ulcerative colitis. In another embodiment, the invention pertains to a method for treating ulcerative colitis in a human which comprises the steps of (a) obtaining from a human a colon epithelial cell extract containing a tropomyosin isoform associated with ulcerative colitis; (b) purifying the tropomyosin isoform until the tropomyosin isoform is substantially homogeneous; (c) developing an antibody which binds to the tropomyosin isoform; and (d) orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of the antibody to bind to the tropomyosin isoform associated with ulcerative colitis. In yet another embodiment, the invention pertains to a method for treating ulcerative colitis in a human which comprises orally administering to the human a therapeutically effective amount of a tropomyosin isoform associated with ulcerative colitis.
Therapeutic And Diagnostic Methods For Ulcerative Colitis And Associated Disorders
US Patent:
7122336, Oct 17, 2006
Filed:
Feb 5, 2003
Appl. No.:
10/359401
Inventors:
Kiron M. Das - Basking Ridge NJ, US
Assignee:
University of Medicine & Dentistry of New Jersey - New Brunswick NJ
International Classification:
G01N 33/53
US Classification:
435 29
Abstract:
This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic methods for detecting diseases associated with an autoantigen response to hTM in affected tissue.
Tropomyosin Isoforms, And Diagnostic And Therapeutic Uses Therefor
US Patent:
RE43472, Jun 12, 2012
Filed:
Oct 23, 2009
Appl. No.:
12/604840
Inventors:
Kiron M. Das - Basking Ridge NJ, US
Jim Jung-Ching Lin - Iowa City IA, US
Jim Jung-Ching Lin - Iowa City IA, US
Assignee:
University of Medicine and Dentistry of New Jersey - Somerset NJ
University of Iowa Research Foundation - Iowa City IA
University of Iowa Research Foundation - Iowa City IA
International Classification:
C07K 14/00
US Classification:
530350, 530326, 5303871, 5303879, 530806, 4241301, 4241391, 4241781, 4241851, 4241931, 435 71
Abstract:
A novel isoform of tropomyosin is disclosed. The isoform is closely related to epithelial human tropomyosin (hTM) and more particularly to hTM5 except the last coding exon. The novel isoform, is called TC22. Northern blot analysis with TC22-specific probe revealed that normal culture cell lines and normal epithelial tissues expressed very little, if at all, TC22 message, whereas their transformed counterparts and tumor tissues including dysfunction of the alimentary canal, significantly increased the expression of TC22. Assays directed at determining the level of TC22 are useful in diagnostics and therapeutics of dysfunction of the alimentary canal. Specific antibodies and mimics for TC22 are also disclosed for use in diagnostics and therapeutics of dysfunction of the alimentary canal.
Therapeutic And Diagnostic Methods For Ulcerative Colitis And Associated Disorders
US Patent:
2007003, Feb 8, 2007
Filed:
Aug 7, 2006
Appl. No.:
11/500113
Inventors:
Kiron Das - Basking Ridge NJ, US
International Classification:
A61K 39/00
US Classification:
514012000
Abstract:
This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic methods for detecting diseases associated with an autoanticen response to hTM in affected tissue.
Compositions And Methods For Treatment Of Ulcerative Colitis
US Patent:
2005026, Nov 24, 2005
Filed:
May 18, 2005
Appl. No.:
11/132104
Inventors:
Gopala Kovvali - Edison NJ, US
Kiron Das - Basking Ridge NJ, US
Kiron Das - Basking Ridge NJ, US
International Classification:
A61K038/21, G01N033/53, A61K038/17
US Classification:
424085600, 514012000, 435007100
Abstract:
The present invention relates to the identification of TCP-1 gamma as a protein whose expression is decreased in patients with ulcerative colitis and Crohn's disease. This protein interacts with hTM5, which is involved in the pathogenesis of ulcerative colitis. Compositions and methods for diagnosis and treatment, including methods for following up the efficacy of treatment of ulcerative colitis are provided.